Welcome to our dedicated page for IDEXX Laboratories SEC filings (Ticker: IDXX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IDEXX Laboratories, Inc. (IDXX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a NASDAQ-listed, S&P 500 company focused on pet healthcare innovation, veterinary diagnostics, and software, IDEXX uses SEC filings to report financial results, material agreements, and governance changes that matter to shareholders and analysts.
Among the most closely watched documents are annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which describe IDEXX’s business, risk factors, and detailed financial statements, including performance in areas such as the Companion Animal Group, Water, and Livestock, Poultry and Dairy. Current reports on Form 8‑K provide timely updates on specific events, such as quarterly earnings releases, amendments to credit agreements, and board or leadership changes. For example, IDEXX has filed 8‑Ks describing an amendment to a credit agreement that provides unsecured revolving and term loan facilities for general corporate purposes, as well as filings that furnish earnings press releases.
Investors can also use this page to monitor proxy statements for information on board structure and executive compensation, and Form 4 insider transaction reports when available, which show purchases and sales of IDXX shares by directors and officers.
Stock Titan enhances these filings with AI-powered summaries that explain key points in plain language, helping users navigate lengthy documents such as 10‑Ks and 10‑Qs. Real-time updates from EDGAR mean new IDEXX filings appear promptly, while AI highlights important items like changes in leverage arrangements, governance updates, and trends in reported results. This makes it easier to understand how IDEXX’s regulatory disclosures relate to its veterinary diagnostics, software, and animal health businesses.
Nimrata Hunt, Executive Vice President of IDEXX Laboratories, reported transactions in the issuer's common stock (ticker IDXX). The filing shows a sale and subsequent option exercises that largely offset each other. On 08/11/2025 she sold 1,200 shares at $656.5335, leaving 16,806.9435 shares held directly. On 08/12/2025 she acquired shares through the exercise of previously granted options: 560 at $178.26, 483 at $206.94, and 183 at $544.08, bringing direct beneficial ownership to 18,032.9435 shares. The filing also notes 160 shares held indirectly, jointly with a spouse. The exercised options correspond to grants that became exercisable in one installment on Feb 14, 2023, Feb 14, 2024, and Feb 14, 2025.
Form 144 notice for IDEXX Laboratories (IDXX) reports a proposed sale of 407 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $264,533.53. The filing lists the company's outstanding shares as 80,004,694, so the proposed sale represents approximately 0.00051% of outstanding stock. The acquisition history provided shows the shares originated from multiple Employee Stock Purchase Plan purchases and a Restricted Stock grant, with acquisition dates ranging from 06/30/2021 through 03/29/2024. The filer certifies they are not aware of undisclosed material adverse information and uses Morgan Stanley as the executing broker. The proposed approximate sale date is 08/12/2025.
Sharon E. Underberg, EVP, General Counsel & Corporate Secretary of IDEXX Laboratories (IDXX), filed a Form 4 reporting stock and option activity on 08/08/2025 and 08/12/2025. The filing shows non-derivative and derivative transactions including an acquisition of 5,450 common shares (08/08/2025) and a same-day disposition of 5,450 common shares (08/08/2025), and an acquisition of 183 common shares (08/12/2025). The record lists beneficial ownership following the reported transactions at 6,338.6539 shares.
The Form 4 also reports derivative holdings: a non-qualified stock option covering 5,450 underlying shares (exercise price shown as $206.94) and an incentive stock option covering 183 underlying shares (exercise price shown as $544.08). The filing includes an explanatory note that 28.7090 shares were purchased under the Issuer Employee Stock Purchase Plan during March and June 2025. The form is signed by an attorney-in-fact on behalf of Ms. Underberg on 08/12/2025.
Jonathan Jay Mazelsky, who is reported as a Director and the President and CEO of IDEXX Laboratories, reported an insider transaction involving common stock and a related option. The Form 4 shows an acquisition of 183 shares of common stock on 08/08/2025 at a price of $598.488 per share, with reported beneficial ownership following the transaction of 83,494.3016 shares (direct).
The filing also discloses a Premium Incentive Stock Option tied to 183 underlying shares with an exercise/conversion price of $598.488. The explanatory note states the option was granted at a 110% premium to the closing price on February 12, 2021 and became exercisable in one installment on February 14, 2025. The Form 4 is signed by an attorney-in-fact on behalf of Mr. Mazelsky.
Andrew Emerson, EVP, CFO and Treasurer of IDEXX Laboratories (IDXX), reported insider transactions dated 08/07/2025. The filing shows an acquisition of 1,849 common shares at $141.60 and a disposition of 402 common shares at $650.06. Following the reported transactions, beneficial ownership is shown as 4,272.778 shares (direct) after the acquisition and 3,870.778 shares (direct) after the disposition. The filing notes 27.3420 shares purchased under the employee stock purchase plan on March 31, 2025 and June 30, 2025, and references a grant of an option to buy 1,849 shares that vested on February 14, 2022. The form is signed by an attorney-in-fact on 08/11/2025.
Idexx Laboratories insider transaction disclosed via Form 144. The filing reports a proposed sale of 1,200 common shares through Morgan Stanley Smith Barney with an aggregate market value of $787,840.20. The shares were acquired by exercise on 08/06/2025 and payment was made in cash. With 80,004,694 shares outstanding, the proposed sale represents approximately 0.0015% of the company’s outstanding common stock.
The filing also lists three sales by NIMRATA K HUNT on 08/06/2025 totaling 7,143 shares and gross proceeds of $4,503,160.86. The filer affirms they are not aware of any material nonpublic adverse information about the issuer.
Idexx Laboratories executive Nimrata Hunt reported option exercises and market sales on 08/06/2025. The filing shows conversion of non-qualified stock options into common stock for 1,218, 5,865 and 5,711 shares at strikes of $141.60, $178.26 and $206.94 respectively, and three open-market sales totaling 7,143 shares at prices between $630.6891 and $630.9087. The reporting person owned 25,149.9435 shares before the sales and owned 18,006.9435 shares directly after the transactions, with an additional 160 shares held indirectly (jointly with spouse). The Form documents the mechanics of option-to-share conversion and subsequent sales without stating motives.
Jonathan Jay Mazelsky, President and CEO and a director of IDEXX Laboratories (IDXX), reported a series of transactions dated 08/06/2025. He acquired 29,260 shares by exercising non-qualified stock options at an exercise price of $67.85 per share and sold a matching total of 29,260 common shares the same day in multiple tranches at reported weighted-average prices between $626.9024 and $639.3718 per share. The reported sales reduced his direct holdings from 112,571.3016 shares to 83,311.3016 shares. Based on the reported quantities and prices, the aggregate gross proceeds from the sales are approximately $18.49 million. The filing also references an option grant to buy 41,260 shares that became exercisable in five annual installments beginning 02/14/2017.
Michael Lane, Executive Vice President of Idexx Laboratories (IDXX), reported multiple stock and option transactions dated 08/06/2025. The filing shows acquisitions of 1,286 and 7,125 shares (prices listed as $206.94 and $288.78), and dispositions of 5,631, 2,480 and 300 shares at weighted-average prices of $627.5634, $627.9911 and $628.8866, respectively. After these transactions the filing reports total direct beneficial ownership of 7,131.9435 shares and an additional 592 shares held indirectly by the reporting person’s spouse in an IRA.
The filing also lists non-qualified stock option awards related to the reporting person: a right associated with 1,286 underlying shares (exercise price $206.94) and a right associated with 7,125 underlying shares (exercise price $288.78). Explanations note prior grants exercisable in installments beginning in 2020 and 2021 and purchases of 28.7090 shares under the issuer’s Employee Stock Purchase Plan.
IDEXX Laboratories Inc. filed a Form 144 to register the proposed sale of 5,450 shares of common stock, with an aggregate market value of $3,551,220.00, to be sold on NASDAQ through Morgan Stanley Smith Barney LLC. The filing lists 80,004,694 shares outstanding and shows an approximate sale date of 08/08/2025.
The shares were acquired via a stock option exercise on 08/08/2025 and paid in cash. The filer reports "Nothing to Report" for securities sold during the past three months and includes the standard attestation about material nonpublic information and trading-plan language. The provided content does not show a populated notice date or signature block.